Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer

BACKGROUND: The very aggressive nature and low survival rate of pancreatic ductal adenocarcinoma (PDAC) dictates the necessity to find novel efficacious therapies. Recent evidence suggests that phosphoinositide 3-kinase (PI3K) and 3-phosphoinositide-dependent protein kinase 1 (PDK1) are key effector...

Descripción completa

Detalles Bibliográficos
Autores principales: Emmanouilidi, Aikaterini, Fyffe, Chanse A., Ferro, Riccardo, Edling, Charlotte E., Capone, Emily, Sestito, Simona, Rapposelli, Simona, Lattanzio, Rossano, Iacobelli, Stefano, Sala, Gianluca, Maffucci, Tania, Falasca, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518649/
https://www.ncbi.nlm.nih.gov/pubmed/31088502
http://dx.doi.org/10.1186/s13046-019-1191-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518649/
https://www.ncbi.nlm.nih.gov/pubmed/31088502
http://dx.doi.org/10.1186/s13046-019-1191-2

Ejemplares similares